SARS-CoV-2 S protein RBD containing C-terminal His Tag. The protein was expressed in human 293 cells (HEK293). It contains amino acids Arg 319 - Lys 537.
SARS-CoV-2 (COVID-19) Spike Neutralization Antibody is supplied in PBS.
Formulierung:
Liquid
Application Verdünnung:
Optimal dilutions for each application to be determined by the researcher.
Figure 1. ACE2-RBD binding inhibition by Antibody SD9859 (1C7).An ELISA was performed to test whether SARS-CoV-2 (COVID-19) Spike RBD Antibody, SD9859 inhibits the binding of RBD proteins (from the receptor binding domain of the SARS-CoV-2 spike protein wildtype and alpha variant, respectively) to ACE2, a cellular receptor for SARS-CoV-2. The RBD proteins were used as coating antigens at 1 &mu,g/mL. Antibody SD9857 was added at the concentrations indicated followed by the addition of 20 ng/ml human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. SD9859 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains.
Figure 2. Pseudovirus neutralization assay with Antibody SD9859 (1C7). A pseudovirus neutralization assay was performed to test whether SD9859 inhibits the entry of SARS-CoV-2 spike carrying pseudovirus into 293T-hsACE2 cells. The virus-like particles carry a luciferase reporter which can be detected using Promega&rsquo,s Renilla-Glo Luciferase Assay System. Antibody SD9859 was added to the cells at the concentrations indicated together with the virus-like particles. After 72 hrs incubation infectivity was determined by measuring relative light units (RLU) produced by the introduced luciferase reporter. The RLUs obtained with the no-antibody control were set as 100% infectivity, i.e., 0% inhibition). SD9859 exhibited a dose dependent neutralizing effect on the wild-type SARS-CoV-2 pseudovirus.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
